HIGHfield_logo_horizontal_FINAL_EnglishPost navigationPrevious: HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers